Regencell Bioscience (RGC) has had the highest return since January 1, 2025 by a US stock in the Biotechnology Industry, returning 12,699.4%.
| ASSET | % RETURN |
|---|---|
Regencell Bioscience (RGC) | 12,699.4% |
Abivax SA American Depositary Shares (ABVX) | 1,059.12% |
Nanobiotix (NBTX) | 559.49% |
Lixte Biotechnology (LIXTW) | 553.57% |
Anbio Biotechnology Class A Ordinary Shares (NNNN) | 511.41% |
Palvella Therapeutics (PVLA) | 466.58% |
Neuphoria Therapeutics (NEUP) | 433.15% |
ABVC BioPharma (ABVC) | 408.47% |
I-Mab (IMAB) | 408.24% |
Quantum BioPharma (QNTM) | 385.53% |
Monopar Therapeutics (MNPR) | 351.77% |
Protagenic Therapeutics (PTIXW) | 329.23% |
DBV Technologies (DBVT) | 292.1% |
Matinas BioPharma (MTNB) | 286.45% |
Sonnet Biotherapeutics (SONN) | 285.62% |
Celcuity LLC (CELC) | 282.07% |
ATAI Life Sciences (ATAI) | 281.75% |
Cidara Therapeutics (CDTX) | 276.21% |
GRAIL, LLC (GRAL) | 267.82% |
Ainos (AIMDW) | 266.53% |
CervoMed (CRVO) | 262.5% |
Lineage Cell Therapeutics (LCTX) | 230.85% |
Galectin Therapeutics (GALT) | 230.53% |
CytomX Therapeutics (CTMX) | 226.73% |
AquaBounty Technologies (AQB) | 218.88% |
